Supplementary Material for: ISPAD Clinical Practice Consensus Guidelines 2024: Diabetes Technologies: Insulin Delivery

A SUMMARY OF WHAT IS NEW OR DIFFERENT?

This chapter focuses on insulin pump therapy, with a greater emphasis on glucose-responsive integrated technology that is feasible with the use of automated insulin delivery (AID) systems. The chapter also includes connected insulin pens and insulin pump therapy without AID functionality. As behavioral, psychosocial, and educational considerations of insulin delivery devices are a central part of diabetes self-management and use of insulin delivery devices, these topics are also addressed.

Updates and Changes to previous recommendations include:
1. Additional details on AID incorporating data from clinical trials complemented by real-world evidence.
2. Additional focus and details that delineate potential benefits of these systems with new data for youth of all ages, from preschoolers to young adults
3. New data regarding insulin pump therapy that does not involve AID (non-AID)
4. An emphasis on approaches to optimize outcomes for all forms of insulin delivery devices, including insulin pump therapy as well as behavioral, psychosocial, and educational considerations for optimizing the daily use of these devices.
5. A summary of the growing evidence of the technology benefits beyond glycemic outcomes including person-reported outcomes and experience measures and impacts on the quality of life of youth and their caregivers.